Summary.-Detailed serological studies have been undertaken in a small group of cancer patients receiving nonspecific immunotherapy with Corynebacterium parvum (C. parvum). These patients included 4 cases of recurrent malignant melanoma, 2 of stomach cancer and 2 of recurrent breast cancer. They all received an initial i.v. infusion of 20 mg of a formol killed suspension of C. parvum followed by 2 mg (i.m.) at weekly intervals for 10-11 weeks.
DURING recent years, considerable interest has been shown in the use of adjuvants such as BCG for specific and nonspecific immunotherapy of tumours in man (for example, Morton et al., 1970; Mathe et al., 1973; Gutterman et al., 1973) .
Our own attention has been focussed upon the possible clinical value of formol killed suspensions of C. parvurm. Detailed studies undertaken in mice have demonstrated convincingly that these preparations can inhibit the growth of transplanted syngeneic tumours of both chemical and viral origin (Woodruff and Boak, 1966; Halpern et al., 1966; Woodruff and Dunbar, 1973) . On the basis of the experience gained in animal tumour systems, we have recently administered C. parvum to a limited number of cancer patients with poor prognosis. Although it is still too early to assess the clinical value of the treatment used, we report in the present paper the results of detailed serological studies we have undertaken in some of these patients, not only because they are of some fundamental importance but also as a guide to other investigators in this field.
During these studies we have determined the effect of repeated C. parvurm administration on the levels of immunoglobulin classes and other serum proteins.
Furthermore, because the IgG subclasses (namely IgGI, IgG2, IgG3 and IgG4) differ widely in their in vitro and in vivo properties (Spiegelberg, 1974) , including their capacity to block the cell mediated destruction of tumour cells in vitro (Jose and Skvaril, 1974) , we have also investigated the effect of C. parvum therapy upon individual IgG subclass levels. As far as we are aware, the present results are the first reporting the effects of any form of immunotherapy on subclass levels. Finally, we have also monitored the patients' sera for antibodies to C. parvum and have attempted to assess the relevance of these to the immunoglobulin changes.
MATERIALS AND METHODS
The 8 patients studied comprised 2 with locally recurrent breast cancer following 3-4 years after simple mastectomy and radiotherapy (G.W. and E.B.); 4 with malignant melanoma who, 9 months to 9 years after the initial tumour, had extensive lymph node involvement, local recurrence or multiple subcutaneous metastases, or some combination of these (M.S., M.F., R.B., A.J.); and 2 with carcinoma of the stomach with extensive lymph node involvement who were treated by gastrectomy 9 days (E.P.) and 21 days (J.J.) previously. Clinical data concerning these and other patients treated with C. parvum will be reported fully in due course.
The serum protein levels observed before therapy are recorded in Table I . With the exception of G.W. (see later), all patients received an initial i.v. infusion of 20 mg of a formol killed suspension of C. parvum followed by 2 mg (i.m.) at weekly intervals for 10-11 weeks. The C. parvum used (CN6134 Batch EZ174) was supplied by the Wellcome Research Laboratories, Langley Court, Beckenham. To minimize the febrile reactions which often follow i.v. administration of C. parvum (Woodruff et al., 1974a) , the patients also received aspirin. On one occasion (patient M.S.) the administration of C. parvum was temporarily suspended for 2 weeks because of the appearance of a skin rash. One patient (G.W.) had received a single i.v. infusion of 47 *6 mg of C. parvum some 5 months before commencing the weekly course of intramuscular injections.
The serum samples for analysis were always obtained immediately before each C. parvum injection and were stored at -20°C before assay.
The IgM, IgA, IgG, IgG subclass and oc2M levels in the sera were determined by the Mancini radial immunodiffusion technique (Mancini, Carbonara and Heremans, 1965) . A complete range of standards was included on every plate and all the test samples were assayed in duplicate. The antisera to IgG, IgA and IgM were purchased from Wellcome Reagents Ltd, Langley Court, Beckenham, while the antiserum to a2M was produced in our own laboratory as previously described (Tunstall et al., 1975 (Shakib et al., 1975) . The IgE levels were determined by a radioimmunoassay procedure employing the Phadebas IgE test kit (purchased from Pharmacia G.B. Ltd, London). This assay was performed according to the manufacturer's instructions.
The pregnancy oc-macroglobulin levels were determined by an immunoassay procedure employing antibody-enzyme conjugates. This procedure has been described in detail elsewhere (Stimson and Sinclair, 1974) .
Antibodies to C. parvum were measured in the sera by a latex agglutination test (Woodruff, McBride and Dunbar, 1974b) . The results are expressed as log2 reciprocal of the end point dilution. In certain instances sera were fractionated on Sephadex G-200 columns and the presence of antibody activity in the 19S, 1OS, 7S and 4 5S peaks was assessed by the same technique. On other occasions, dilutions of sera (see Tables  II and III) were absorbed at 37 'C for 30 min and overnight at 4°C (x 3) with one-tenth of a volume of packed C. parvum organisms. Anti-C. parvum titres, IgG and IgG subclass levels were measured before and after absorption to give some indication of the amount of IgG which was anti-C. parvum antibody.
Screening for antinuclear factors was performed by the qualitative rapid slide test Note: All anti-C. parvurm titres after absorption were< 1og22 AB3 titre by the agglutination test.
(Hyland, California) while the presence or absence of rheumatoid factor was established by the latex slide test (Hoechst Pharmaceuticals, Hounslow, England). Sera positive in the latex slide test were further examined by the Rose-Waaler procedure employing sensitized sheep cells (Cruickshank, 1969) .
RESULTS
The effect of C. parvurn therapy on the levels of serum immunoglobulins and other proteins is illustrated in Fig. 1-10 . In all the figures the protein levels have been expressed as a percentage of the value observed immediately before therapy (Table I ). For ease of presentation, we have plotted only the changes noted during the initial 50 days following commencement of therapy, but in general a similar pattern was apparent over the entire period of observation (70-128 days). In all cases, the administration of C. parvum was accompanied by an increase in the serum IgG level (Fig. 1 ). This increase was often apparent within 2 weeks of the initial C. parvum injection and the levels generally remained elevated throughout the period of treatment. On occasions, the IgG levels increased to almost twice the pretreatment value (see E.B. occuir in the first 2 weeks of therapy and that they were generally transient in nature and could sometimes be followed by a sharp decline (see J.J. and M.S., Fig. 3 ) were particularly interesting. The IgE levels showed an initial early increase in 4/7 patients but in all cases this was followed by a decline. Indeed, in 4 cases the IgE levels had fallen well below their pretreatment values within 7 weeks of commencing therapy (see M.F., E.P., E.B. and J.J., Fig. 4 ). It should be noted that the IgE levels in patient M.S. were less than 4 I.U. in 7/8 assays performed on serum samples obtained within 7 weeks of commencing therapy.
The effect of C. parvum therapy upon IgG subclass levels is shown in Fig. 5-8 being observed in only 3 and 2 patients respectively (Fig. 7, 8 ). The C. parvum protocol had a variable effect on the levels of the 2 oc-macroglobulins studied. In general, the serum x2M levels were largely unchanged (Fig. 9) , this in itself being a good indication that the changes observed in the levels of other serum proteins were probably not due to haemoconcentration or haemodilution. In contrast, however, variations in pregnancy xM levels were noted (Fig. 10) (M.S., M.F.) and a decline in the third patient (R.R.). All the patients investigated had preexisting antibodies to C. parvum (see Fig. 11 (Fig. 12) . It should also be noted that the response of certain patients were rather poor (e.g., A.J., J.J. and M.S.). The absorption of sera with C. parvum resulted in an appreciable decrease in the overall IgG levels (Table III) and also affected the levels of individual IgG subclasses (Table III) Spiegelberg, 1974) . From this point of view, its preferential elicitation by (=,. parvum would appear to be of little advantage to aniy tumour cointrol mechanisms involviing cytolysis or opsonization of tumour cells. In this respect it is interesting to note that in vitro studies in murine systems strongly suggest that the anti-tumour effect of (. parvurm is exerted through macrophages (Olivotto and Bomford, 1974; Ghaffar et al., 1974; G(haffar, Cullen and Woodruff, 1975) . On the other hand, Jose and Skvaril (1974) (Spiegelberg, 1974) . Further studies on the immune response of mice to SRBC (Warr and James, 1975) The estimation of total IgG and individual IgG subclass levels in patients sera before and after absorption with C. parvum indicated that increases in total IgG and individual IgG subclasses were attributable in part to the development of specific antibodies to C. parvum. Although these absorption studies are only preliminary, the observation in 2 of 3 sera examined that the major effect of absorption was on the IgG2 subclass level is of interest to previous observations in man that the antibodies elicited following challenge with carbohydrate antigens are predominantly associated with this subclass (Yount et al., 1968) . Thus, the marked increase in IgG2 noted in the present study might also represent a preferential subclass response to the antigenic polysaccharide component of C. parvum (Dawes, Tuach and McBride, 1974) but absorption studies will be necessary to establish this possibility. Furthermore, because of possible nonspecific absorption effects, we cannot exclude the possibility of "nonspecific" IgG synthesis that could follow lymphoid (or more specificallyB) cellhyperplasia induced by C. pzrvum. Such a response has been suggested to occur following the administration of some antigens as well as other immunopotentiating agents (Humphrey, 1963; Moticka, 1974) . The absence of marked changes in autoantibody levels and the levels of pre-existing antibodies to heterologous red cells and a panel of common Esch. coli 0 antigens (personal observations) tends to argue against the stimulation of pre-existing clones by C. parvum as contributing to a general Ig increase; however, further work is required to clarify this potentially important issue.
At the present time we have no satisfactory explanation for the inconsistent changes noted in the levels of IgA, IgM and IgE. While in the present studies the IgE levels showed a transient increase in a number of patients (for example, J.J.), it should be stressed that in one patient (not included in the present study) with bronchogenic carcinoma a single i.v. injection of 46 8 mg of C. parvum resulted in a 90-fold increase in IgE levels. Subsequent investigations revealed that this patient had a history of allergic asthma, indicating that the monitoring of IgE is both advisable and informative. The observation that C. parvum caused an increase in the IgA levels of both stomach cancer patients and one breast cancer patient, but was without effect in the 4 melanoma patients studied, is of interest and requires further investigation.
The significance of the marked differences in the initial levels and subsequent variations of pregnancy aM, remain to be established. However, detailed studies in other patients with tumours (W. H. Stimson, unpublished) suggest that increases in pregnancy aM are indicative of tumour growth and metastases, whereas a fall in the levels is suggestive of tumour regression.
The presence of high levels of preexisiting antibodies to C. parvum and their marked increase following challenge with this organism has previously been observed in mice (Woodruff et al., 1974b) . This observation, together with in vitro studies indicating that C. parvum may activate both the classic and alternate pathways of complement (McBride et al., 1975) , may account for some of the sidereactions associated with the administration of this material and emphasizes the importance of monitoring the level of these antibodies.
Another interesting point to arise from this study was that from the limited results we have to date, albeit using relatively insensitive tests, the risk of autoreactivity may not be as great as might have been expected from animal experiments (McCracken, McBride and Weir, 1971; Cox and Keast, 1974; McBride, Jones and Weir, 1974) . Nevertheless, the observation that rheumatoid factor-like substances may appear transiently in C. parvum treated patients highlights the importance of monitoring the serum of adjuvant treated patients for autoantibodies. In this respect, the use of more sensitive procedures than used in the present study would be desirable, e.g. the fluorescence procedure for antinuclear factor.
